|
Svetlana Mojsov, PhD
Lulu Chow Wang and Robin Chemers Neustein
Research Associate Professor
The Rockefeller University
Svetlana Mojsov was born in Skopje, North Macedonia (former Yugoslavia). She graduated from the University of Belgrade in 1971 with a degree in physical chemistry and in 1972 was accepted in the graduate program at Rockefeller University in the laboratory of Professor Bruce Merrifield. Mojsov obtained PhD in 1978 and remained in Merrifield group as Postdoctoral Associate and later as Research Associate.
In 1983 Mojsov was appointed a member of the Endocrine unit at Massachusetts General Hospital, Instructor of Medicine at Harvard Medical School, and inaugural director of the Howard Hughes Medical Institute peptide core facility at MGH. Her research between 1983 and 1990 at the Endocrine Unit established that GLP-1 is an incretin and has therapeutic potential for treatment of Type 2 diabetes. In 1990 Mojsov returned to Rockefeller University as Assistant Professor and was promoted to Research Associate Professor in 2002.
Mojsov is a co-inventor on series of patents licensed by the Massachusetts General Hospital to Novo Nordisk Pharmaceutical company that developed GLP-1 analogs, liraglutide and later semaglutide, for Type 2 diabetes and obesity.
Mojsov’s work on GLP-1 has received national and international recognition including the following awards and prizes: 2023-Vinfuture Prize for Innovation; 2023-Nature’s 10 Influential Scientists; 2024-Pearl Meister Greengard Award; 2024-Lasker-DeBakey Medical Clinical Award; 2024-Tang Prize; 2024-Princess of Asturias Prize; 2025-Warren Tri-annual Prize; 2025-BBVA Foundation Frontiers of Knowledge Award; 2025-Breakthrough Prize; 2025-Election to the National Academy of Sciences USA; 2025-Distinguished Medical Science Award; 2025-Spector Prize from Columbia University, 2025-Helen Dean King Award from Wistar Institute, 2026 Kimberly Prize from Northwestern University Feinberg School of Medicine.
| 
